A multidisciplinary approach to dosing nusinersen for spinal muscular atrophy
- 1 October 2019
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology Clinical Practice
- Vol. 9 (5), 424-432
- https://doi.org/10.1212/cpj.0000000000000718
Abstract
Background In December 2016, nusinersen gained FDA approval as the first pharmacologic treatment for spinal muscular atrophy (SMA), a disorder of motor neurons and the leading genetic cause of infant mortality. Nusinersen's intrathecal delivery requirement, strict dosage protocol, and accelerated FDA approval presented a challenge to health care centers hoping to implement treatment of patients with SMA. Scheduling logistics, combined with the specific ventilatory, anesthetic, and spinal access needs of this patient population, requires extensive coordination of care. This complexity, in addition to the high cost of treatment, may lead to overburdening of an institution's dosing resources, causing delays in treatment initiation and limiting patients' access to therapy and may result in barriers to coverage. Methods We initiated a comprehensive stepwise protocol to maximize patient inclusion, as well as safety and efficiency outcome measures. This retrospective cohort study reviews the dosing process. Results As a result of immense collaborative efforts involving care coordination of patients and families, in addition to health providers in the divisions of neurology, anesthesiology, pulmonology, orthopedics, interventional radiology, physical therapy, and neurosurgery, we have successfully dosed 62 SMA patients. Throughout this process, we have improved anesthetic techniques, as well as minimized procedural complications and missed scheduled doses. Conclusion We present here recommendations for safe and effective implementation of nusinersen utilizing a multidisciplinary approach, based on our 1 and a half year experience at a tertiary care children's hospital.Keywords
This publication has 16 references indexed in Scilit:
- Results from a phase 1 study of nusinersen (ISIS-SMN Rx ) in children with spinal muscular atrophyNeurology, 2016
- Intrathecal Injections in Children With Spinal Muscular AtrophyJournal of Child Neurology, 2016
- Spinal Muscular AtrophiesPublished by Elsevier BV ,2015
- Antisense Oligonucleotides Delivered to the Mouse CNS Ameliorate Symptoms of Severe Spinal Muscular AtrophyScience Translational Medicine, 2011
- Tuberculosis Immunopathology: The Neglected Role of Extracellular Matrix DestructionScience Translational Medicine, 2011
- Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse modelGenes & Development, 2010
- Antisense Masking of an hnRNP A1/A2 Intronic Splicing Silencer Corrects SMN2 Splicing in Transgenic MiceAmerican Journal of Human Genetics, 2008
- Spinal Muscular Atrophy: Clinical Classification and Disease HeterogeneityJournal of Child Neurology, 2007
- A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophyProceedings of the National Academy of Sciences of the United States of America, 1999
- Identification and characterization of a spinal muscular atrophy-determining geneCell, 1995